Markus Warmuth
Jnana Therapeutics (United States)(US)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Click Chemistry and Applications, Fibroblast Growth Factor Research, Estrogen and related hormone effects
Most-Cited Works
- → The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity(2012)8,404 cited
- → Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases(2016)909 cited
- → Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors(2010)596 cited
- → The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1(2017)581 cited
- → Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma(2010)553 cited
- → Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation(2008)512 cited
- → H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers(2018)500 cited
- → Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point(2015)458 cited
- → Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1(2018)436 cited
- → Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials(2013)408 cited